Objective:

To identify changes reported by patients in their skin, hair, and nails related to weight management treatment with GLP-1 receptor agonists, including the frequency of dermatologic effects associated with weight loss.

Approach:

• Survey Development and Administration: An anonymous survey was conducted among patients undergoing GLP-1RA weight management therapy, focusing on dermatologic, muscular, and aesthetic effects.
• Statistical Analysis: Descriptive statistics were used to summarize patient-reported outcomes, with Cochran–Armitage trend tests assessing adverse outcomes across weight loss categories.

Key Findings:

• Patients reported improvements in inflammatory skin conditions such as psoriasis and hidradenitis suppurativa.
• With higher weight loss percentages, adverse dermatologic effects such as skin sagging, hair loss, and decreased facial volume became more pronounced.
• 72% of patients with >20% weight loss reported skin sagging; 52% reported hair loss.

Interpretation:

The study identifies a correlation between significant weight loss from GLP-1RA therapy and increased reports of negative dermatologic outcomes.

Limitations:

• The study relies on self-reported data, which may be subject to bias.
• Further research is needed to assess the frequency and management of these dermatologic effects.

Conclusion:

Dermatologists should educate patients on potential dermatologic effects of GLP-1RA therapy.